News Summary
Researchers from San Diego have been awarded the prestigious Lasker Award for their remarkable work in developing treatments for cystic fibrosis. Paul A. Negulescu, Tito Gonzalez, and Michael J. Welsh have made significant contributions to understanding the CFTR protein and developing the transformative triple-drug combination treatment known as Trikafta. The recognition underscores their dedication to improving the lives of cystic fibrosis patients and advancing medical research in this field.
San Diego Scientists Awarded 2025 Lasker Award for Breakthrough Cystic Fibrosis Treatment
San Diego, CA – Paul A. Negulescu, a researcher at Vertex Pharmaceuticals, and Tito Gonzalez from Integro Theranostics, along with Michael J. Welsh from the University of Iowa, have been honored with the prestigious 2025 Lasker Award for their significant contributions to the treatment of cystic fibrosis, a genetic disorder that can be life-threatening. The award recognizes the trio’s groundbreaking work in understanding and developing therapeutic strategies for this serious condition.
Cystic fibrosis affects various organs, primarily the lungs, leading to severe respiratory complications and decreased life expectancy. The Lasker Award, known as one of the highest accolades in the biomedical field, highlights major medical advances that significantly enhance patient quality of life and longevity; many recipients of this award later achieve the esteemed Nobel Prize.
Significant Advances in Cystic Fibrosis Treatment
The research conducted by Negulescu, Gonzalez, and Welsh was pivotal in elucidating the function of the CFTR protein and identifying its defects in patients suffering from cystic fibrosis. Their efforts led directly to the development of small molecules aimed at correcting the malfunctioning CFTR proteins, which are vital in maintaining proper lung function.
A notable outcome of their research is the creation of a triple-drug combination treatment, known as Trikafta, which addresses various deficiencies of the CFTR protein and has transformed cystic fibrosis into a more manageable condition for approximately 90% of patients. Approved in 2019, Trikafta is a combination of three drugs – ivacaftor, tezacaftor, and elexacaftor – each targeting specific mutations causing the disease.
Historical Context of Treatment Development
The pathway to Trikafta began with the initial approval of ivacaftor in 2012, which was specifically for patients presenting with a certain CFTR mutation. Following this, researchers introduced lumacaftor to aid in the maturation of the ΔF508 mutation, although it had shortcomings that warranted further research. Eventually, lumacaftor was succeeded by tezacaftor, enhancing treatment effectiveness.
Through ongoing studies, elexacaftor was discovered, contributing to the formulation of Trikafta. This therapeutic breakthrough has substantially improved the quality of life for many cystic fibrosis patients, reducing the occurrence of lung infections and decreasing the necessity for lung transplants and hospital admissions.
Hope for the Future
The recognition of Negulescu and Gonzalez, alongside Welsh, emphasizes the impact of their work on the advancement of cystic fibrosis treatment. As they continue their research, they aim to find solutions for the remaining 5-10% of cystic fibrosis patients who do not respond positively to Trikafta. Their ongoing efforts reflect a dedication to expanding treatment options and enhancing the prognosis for all individuals affected by this challenging genetic disorder.
Receiving the Lasker Award has been described by the awardees as an affirmation of their hard work and commitment to the field. It not only acknowledges their past achievements but also serves as an inspiration for future medical research addressing cystic fibrosis and other genetic conditions.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Stat News: Lasker Award for Cystic Fibrosis Treatments
- San Diego Union Tribune: San Diego Scientists Win Lasker Award
- The Scientist: Triple Drug Combination for Cystic Fibrosis Wins Lasker Award
- The New York Times: COVID Symptoms and Stomach Pain
- Google Search: Cystic Fibrosis Treatment
